Table. Phenotypic drug susceptibility testing and whole genome sequencing results, first cultured (baseline) Mycobacterium tuberculosis isolate, Germany, October 2023.
| Antibiotic | Mutation | Interpretation | MIC (MGIT) mg/L |
|---|---|---|---|
| Isoniazid | fabG1 -15c > t | R | > 1 |
| KatG S315T | R | ||
| Rifampicin | RpoB I491F | R | 0,5 |
| Rifabutin | RpoB I491F | R | 0,5 |
| Ethambutol | EmbB M306I | R | > 5 |
| Pyrazinamide | pncA 73_del_g | R | > 100 |
| Moxifloxacin | GyrA D94G | R | > 1 |
| Levofloxacin | GyrA D94G | R | > 1 |
| Bedaquiline |
rv0678 138_ins_g rv0678 193_del_g |
R | 2 |
| R | |||
| Clofazimine |
rv0678 138_ins_g rv0678 193_del_g |
R | > 1 |
| R | |||
| Linezolid | RplC C154R | R | 1 |
| D-cycloserine | None | S | ≤ 16 |
| Delamanid | None | S | ≤ 0,06 |
| Amikacin | None | S | ≤ 1 |
| Pretomanid | None | S | ≤ 0,5 |
del: deletion; ins: insertion; MGIT: mycobacterial growth indicator tube; MIC: minimal inhibitory concentration; R: resistant; S: susceptible.
Antimicrobial susceptibility testing was performed with BD BACTEC MGIT960.